Board

Julian Heslop is Chairman of ViiV Healthcare. He became Chief Financial Officer for GSK in 2005, having previously served as SVP, Operations Controller where he was a member of the pharmaceutical operating committee and chaired the capital review team.

Julian qualified as a chartered accountant in 1977 and joined Stoy Hayward as an auditor. He moved to Imperial Brewing and Leisure in 1979 where he worked in a number of management accounting and strategic planning roles. He joined Grand Metropolitan in 1986 and held a number of senior roles in their brewing, property and food businesses and was latterly Group Controller. He joined Glaxo Wellcome in 1998.

Our CEO is Dr Dominique Limet, former Senior Vice President (SVP) and Head of Personalised Medicine Strategy for GSK.

Dominique worked for Ciba-Geigy before joining Glaxo Wellcome in France in 1996. He became Chairman and Managing Director in 2000 and, subsequently, General Manager of GSK France. In 2003 he was appointed SVP and Area Director for GSK's pharmaceutical business in Southern & Eastern Europe.

Dominique holds a Doctorate in Medicine, a specialisation in occupational medicine, and Marketing and Management qualifications earned at Insead. At GSK, Dominique served as a member of GSK's Positive Action Steering Committee and was a board member of the GSK France Foundation, which supported a range of HIV/AIDS-related programmes around the world.

Cees Heiman is Regional President of Europe (which includes Australia/New Zealand on an interim basis) for the Specialty Care Business Unit at Pfizer.

Cees joined Pfizer in 1982 in the Medical Department of Pfizer Netherlands, working on assignments in the Marketing and New Product departments in the Netherlands, US and India. He has held senior positions in Hungary, Japan, Poland, Belgium and Luxembourg. Prior to taking on his current responsibilities at Pfizer, Cees was Regional President of Pfizer Central and Eastern Europe (CEER) and also Country Manager for Italy.

Cees holds bachelor's and master's degrees in Pharmacy from Leiden University in the Netherlands and is a licensed pharmacist.

Dr Zhi Hong is SVP and Head of the Infectious Diseases Centre of Excellence for Drug Discovery at GSK.

Prior to joining GSK in 2007, he was Executive Vice President and Chief Scientific Officer of Ardea Biosciences, Inc., a biopharmaceutical company focused on small-molecule drugs to treat viral diseases, cancer and inflammation.

An inventor on numerous patents and an author of more than 100 research papers, Zhi received his bachelor's degree in Biochemistry from Fudan University in Shanghai and his PhD in Biochemistry from the State University of New York at Buffalo.

Abbas Hussain is President, Emerging Markets at GSK. He joined from Eli Lilly and Company, where he was President, Europe.

Abbas joined Lilly UK in 1988 before moving to Australia in 1990. Over the following 12 years, he held senior positions for the company in the US, Asia, India, Turkey and Germany. He was appointed European Mid-Size Area Director in 2003 and then Vice President of Europe with specific responsibility for the Western European Mid-Size countries, Africa & Middle East Area/Commonwealth of Independent States and Central & Eastern Europe regions.

Abbas has a degree in Medicinal Chemistry & Pharmacology from Loughborough University of Technology, UK.

Duncan Learmouth is SVP, Global Communications at GSK. He was previously Vice President, Global Investor Relations and Competitive Excellence.

Duncan joined Glaxo Wellcome in 1991 and became VP of Investor Relations folowing the merger with SmithKline Beecham in 2000. He was subsequently appointed VP, Global Investor Relations and, in February 2006, added the competitive excellence function to his responsibilities, which included the role of secretary to the CET, GSK's Executive Committee.

Before moving to Glaxo Wellcome, Duncan was with Deloitte and Touche in London, qualifying as a Chartered Accountant in 1991. Duncan was educated at Durham University where he gained a degree in Chemistry.

Ian McCubbin is SVP of Strategy, Logistics and External Supply at GSK.

He joined GSK's manufacturing and supply business in 1985 and over 16 years held a number of senior production, logistics and continuous improvement roles including Site Director at the Ware manufacturing site in the UK. Ian re-joined GSK in 2006, having held senior operational roles in both Merck Generics and IVAX.

Ian holds a degree in Pharmacy from Heriot-Watt University, Edinburgh.

Dr Martin Mackay is the President of Pfizer Global Research & Development (PGRD).

Martin began his career at Pfizer in 1995 as the Director of Discovery Biology in the UK. He held a range of posts in the following years, including SVP, Head of Worldwide Research and Technology and Vice President PGRD, Head of Worldwide Development. Prior to joining Pfizer, Martin operated in several discovery and development roles, culminating with his appointment as Head of Molecular and Cell Biology, CNS Research, at Ciba.

Martin gained a First Class Honours Degree in Microbiology from Heriot-Watt University, Edinburgh and studied for his PhD in Molecular Genetics at the University of Edinburgh.

Dr Ellen Strahlman is SVP and the Chief Medical Officer for GSK.

Prior to joining GSK in August 2008, Ellen was Vice President, Worldwide Business Development at Pfizer. She joined the company in 2005 as the Vice President and Worldwide Therapeutic Area Head for Ophthalmology at Pfizer, Inc. Previously, Ellen worked at Bausch & Lomb, Merck & Co and, more recently, at Novartis and Virgoen Ltd.

Throughout her career, Ellen has been a champion and spokesperson for public health and world heath issues, including HIV. She is a graduate of Harvard University (Biochemical Sciences and Applied Mathematics) and obtained her medical degree from the Johns Hopkins School of Medicine. She has medical qualifications in general surgery and ophthalmology, together with a Masters Degree in Health Sciences.